



1653  
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q92482

PELLETIER, Jerry, et al.

Confirmation No.: 7855

Appln. No.: 09/689,952

Group Art Unit: 1653

Filed: October 12, 2000

Examiner: C.M. Kam

For: COMPOSITIONS AND METHODS INVOLVING AN ESSENTIAL  
STAPHYLOCOCCUS AUREUS GENE AND ITS ENCODED PROTEIN

REVOCATION OF POWER OF ATTORNEY AND  
APPOINTMENT OF NEW ATTORNEYS BY ASSIGNEE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Targanta Therapeutics, Inc., states that it is the assignee of record of the entire right, title, and interest in the above-identified application by virtue of an assignment recorded in the U.S. Patent and Trademark Office at Reel 012203, Frame 0975, and in view of the change in name from PhageTech, Inc., to Targanta Therapeutics, Inc., recorded in the U.S. Patent and Trademark Office at Reel 016245, Frame 0972.

Targanta Therapeutics, Inc., hereby revokes all prior powers of attorney and authorizations of agent given in the above-identified application and appoints all attorneys of SUGHRUE MION, PLLC who are listed under the USPTO Customer Number provided below as its attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under this USPTO Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC.

Targanta Therapeutics, Inc., requests all correspondence for the above-identified application be addressed to the address filed under the same USPTO Customer Number.

WASHINGTON OFFICE:

23373

CUSTOMER NUMBER

The undersigned is authorized to act on behalf of the assignee.

Respectfully submitted,

1/2/06  
\_\_\_\_\_  
Date

Tom Part Ph.D.

\_\_\_\_\_  
Typed or printed name

  
\_\_\_\_\_  
Signature

Chief Scientific Officer

\_\_\_\_\_  
Title